Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Mizuho Maintains Buy on IQVIA Hldgs, Lowers Price Target to $270

Mizuho analyst Ann Hynes maintains IQVIA Hldgs (NYSE:IQV) with a Buy and lowers the price target from $300 to $270.
byBenzinga Newsdesk
March 7, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Mizuho analyst Ann Hynes maintains IQVIA Hldgs (NYSE:IQV) with a Buy and lowers the price target from $300 to $270.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Genmab Showcaseed Data From Robust Development Program Evaluating Epcoritamab in Patients Across a Broad Range of B-Cell Lymphomas at ASH 2022

By Charles Gross
Today, 6:43 AM
Genmab A/S (Nasdaq: GMAB) today announced the results from multiple clinical trials evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody, alone or in combination with other therapies for the treatment of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL

GMAB

Read More

Where 8×8 Stands With Analysts

By Benzinga Insights
Today, 6:43 AM
Over the past 3 months, 6 analysts have published their opinion on 8x8 (NYSE:EGHT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

EGHT